Please use this identifier to cite or link to this item:
Title: Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate.
Authors: Bavetsias, V
Large, JM
Sun, C
Bouloc, N
Kosmopoulou, M
Matteucci, M
Wilsher, NE
Martins, V
Reynisson, J
Atrash, B
Faisal, A
Urban, F
Valenti, M
de Haven Brandon A
Box, G
Raynaud, FI
Workman, P
Eccles, SA
Bayliss, R
Blagg, J
Linardopoulos, S
McDonald, E
First Published: 22-Jul-2010
Citation: J MED CHEM, 2010, 53 (14), pp. 5213-5228
Abstract: Lead optimization studies using 7 as the starting point led to a new class of imidazo[4,5-b]pyridine-based inhibitors of Aurora kinases that possessed the 1-benzylpiperazinyl motif at the 7-position, and displayed favorable in vitro properties. Cocrystallization of Aurora-A with 40c (CCT137444) provided a clear understanding into the interactions of this novel class of inhibitors with the Aurora kinases. Subsequent physicochemical property refinement by the incorporation of solubilizing groups led to the identification of 3-((4-(6-bromo-2-(4-(4-methylpiperazin-1-yl)phenyl)-3H-imidazo[4,5-b]pyridin-7-yl)piperazin-1-yl)methyl)-5-methylisoxazole (51, CCT137690) which is a potent inhibitor of Aurora kinases (Aurora-A IC(50) = 0.015 +/- 0.003 muM, Aurora-B IC(50) = 0.025 muM, Aurora-C IC(50) = 0.019 muM). Compound 51 is highly orally bioavailable, and in in vivo efficacy studies it inhibited the growth of SW620 colon carcinoma xenografts following oral administration with no observed toxicities as defined by body weight loss.
DOI Link: 10.1021/jm100262j
eISSN: 1520-4804
Type: Journal Article
Appears in Collections:Published Articles, Dept. of Biochemistry

Files in This Item:
There are no files associated with this item.

Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.